發(fā)布時(shí)間：2018-04-16 19:23

  本文選題：肝炎 + 丙型��； 參考：《天津醫(yī)藥》2016年12期

【摘要】：目的探討使用聚乙二醇干擾素聯(lián)合利巴韋林(PR)治療的慢性丙型肝炎(丙肝)患者出現(xiàn)營養(yǎng)風(fēng)險(xiǎn)的影響因素。方法選取接受PR治療的慢性丙肝患者175例,測量身高、體質(zhì)量,計(jì)算體質(zhì)指數(shù)(BMI),用營養(yǎng)風(fēng)險(xiǎn)篩查2002(NRS 2002)來進(jìn)行營養(yǎng)風(fēng)險(xiǎn)評估,并分為有風(fēng)險(xiǎn)組(140例)和無風(fēng)險(xiǎn)組(35例)。結(jié)果 2組間年齡、HCV基因型、臨床類型、治療時(shí)間及干擾素或利巴韋林是否減量差異有統(tǒng)計(jì)學(xué)意義(P0.05)。Logistic回歸分析顯示:高齡(OR值16.068,β值2.777)、干擾素減量(OR值3.096,β值1.130)、利巴韋林減量(OR值3.382,β值1.219)以及進(jìn)展至肝硬化的慢性丙肝(OR值5.092,β值1.628)為營養(yǎng)風(fēng)險(xiǎn)的危險(xiǎn)因素;而HCV基因型為非1b型者(OR值0.384,β值-0.957)為營養(yǎng)風(fēng)險(xiǎn)的保護(hù)因素。結(jié)論接受PR治療的慢性丙肝患者營養(yǎng)風(fēng)險(xiǎn)發(fā)生率高。高齡、對PR不耐受、慢性丙肝進(jìn)展為肝硬化的患者為發(fā)生營養(yǎng)風(fēng)險(xiǎn)的獨(dú)立危險(xiǎn)因素,而非1b型HCV感染者不易發(fā)生營養(yǎng)風(fēng)險(xiǎn)。
[Abstract]:Objective to investigate the influence factors of nutritional risk in patients with chronic hepatitis C (C) treated with peginterferon and ribavirin.Methods 175 patients with chronic hepatitis C treated with PR were selected. Height, body mass, body mass index (BMI) and nutritional risk screening (2002(NRS 2002) were measured to evaluate nutritional risk. The patients were divided into two groups: a risk group (n = 140) and a non-risk group (n = 35).Results the genotype and clinical type of HCV between the two groups were analyzed.Logistic regression analysis showed that the OR value was 16.068, 尾 value was 2.777N, OR value was 3.096, 尾 value was 1.130%, ribavirin decrement OR value was 3.382, 尾 value was 1.219) and progression to cirrhosis.The OR value and 尾 value of chronic hepatitis C were 5.092 and 1.628 respectively.The OR value of HCV genotype was 0.384, and 尾 -0.957) was the protective factor of nutrition risk.Conclusion the nutritional risk rate of chronic hepatitis C patients treated with PR is high.Elderly patients with PR intolerance chronic hepatitis C progression to cirrhosis were independent risk factors of nutritional risk but non-1b HCV patients were not susceptible to nutritional risk.
【作者單位】： 天津中醫(yī)藥大學(xué)公共衛(wèi)生教研室;天津市第二人民醫(yī)院;天津肝病研究所;
【基金】：國家科技重大專項(xiàng)課題(2012ZX10005004-003)
【分類號】：R512.63
，

本文編號：1760258